Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in patients newly diagnosed with diffuse large B-cell lymphoma (Abstract LBA7000).
Evan T. Hall, MD, of Fred Hutchinson Cancer Center, discusses findings from the randomized phase II MATRiX trial, which evaluated the efficacy of the ATR inhibitor tuvusertib with or without avelumab in patients with anti–PD-(L)1–refractory Merkel cell carcinoma (Abstract LBA9514).
Lauren Averett Byers, MD, of The University of Texas MD Anderson Cancer Center, describes data on ABBV-706—an investigational antibody-drug conjugate targeting SEZ6—alone or in combination with the anti–PD-1 monoclonal antibody budigalimab in patients with relapsed or refractory small cell lung cancer (SCLC) (Abstract 8008).
Mary-Ellen Taplin, MD, FASCO, of Dana-Farber Cancer Institute, presents the final analysis of the phase III PROTEUS study, which looked at perioperative (neoadjuvant and adjuvant) apalutamide plus androgen-deprivation therapy (ADT) vs placebo and ADT with radical prostatectomy in patients with high-risk localized or locally advanced prostate cancer (Abstract LBA1).
Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515).
